Chad Groer
Overview
Explore the profile of Chad Groer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang A, Groer C, Lu R, Forrest M, Griffin J, Berkland C
Mol Pharm
. 2022 Oct;
19(11):4357-4369.
PMID: 36282296
CpG oligodeoxynucleotides are toll-like receptor 9 agonists capable of inducing potent pro-inflammatory immune responses. Although CpG oligodeoxynucleotides have shown promising antitumor effects, their systemic activity can trigger immune-related toxicity, limiting...
2.
Groer C, Zhang T, Lu R, Cai S, Mull D, Huang A, et al.
Mol Pharm
. 2020 Sep;
17(11):4334-4345.
PMID: 32975949
A carrier-based, immunogenic cell death (ICD)-eliciting platinum(IV) chemotherapeutic agent was synthesized via complexation between an axially derivatized Pt(IV)-tocopherol and hyaluronan (HA)-tocopherol nanocarrier. The resultant HA-Pt(IV) complex demonstrated antiproliferative activity and...
3.
Huang A, Pressnall M, Lu R, Huayamares S, Griffin J, Groer C, et al.
J Control Release
. 2020 Jul;
326:203-221.
PMID: 32673633
Cancer therapies aim to kill tumor cells directly or engage the immune system to fight malignancy. Checkpoint inhibitors, oncolytic viruses, cell-based immunotherapies, cytokines, and adjuvants have been applied to prompt...
4.
Lu R, Groer C, Kleindl P, Moulder K, Huang A, Hunt J, et al.
J Control Release
. 2019 Jun;
306:165-176.
PMID: 31173789
The toll-like receptor 7 and 8 (TLR7/8) agonist Resiquimod (R848) has been recognized as a promising immunostimulator for the treatment of cutaneous cancers in multiple clinical trials. However, systemic administration...
5.
Cai S, Zhang T, Groer C, Forrest M, Aires D, Otte V, et al.
Case Rep Vet Med
. 2018 Nov;
2018:9078537.
PMID: 30402324
This case report documents the diagnosis, treatment, and outcome of a nonresectable oral squamous cell carcinoma in a dog with initial poor prognosis. An approximately 4-year-old female Staffordshire Bull Terrier...
6.
Cai S, Zhang T, Forrest W, Yang Q, Groer C, Mohr E, et al.
Am J Vet Res
. 2016 Sep;
77(9):1005-16.
PMID: 27580113
OBJECTIVE To conduct a phase I-II clinical trial of hyaluronan-cisplatin nanoconjugate (HA-Pt) in dogs with naturally occurring malignant tumors. ANIMALS 18 healthy rats, 9 healthy mice, and 16 dogs with...
7.
Zhang T, Cai S, Groer C, Forrest W, Yang Q, Mohr E, et al.
J Pharm Sci
. 2016 May;
105(6):1891-1900.
PMID: 27155765
The purpose of this study was to develop a safe and efficacious drug delivery platform for sustained release of cisplatin after locoregional administration. We successfully synthesized hyaluronan-cisplatin nanoconjugates (HA-Lys-Pt) using...